Abstract: Disclosed in the present invention is a pacing device for preventing occurrence of atrial fibrillation following premature atrial contraction, including: adjusting values of the number M of atrial events and the number N of premature atrial contraction events to control a pacing control process for preventing the occurrence of atrial fibrillation following premature atrial contraction to take place after a single or more than one premature atrial contraction events, and on the basis of a current p-p? interval, an atrial safe pacing interval and an average atrial interval, setting a smooth transition pacing sequence. The smooth transition pacing sequence avoids atrial compensation intervals caused by the premature atrial contraction and avoids occurrence of a “short-long-short” sequence.

Abstract: A tunable laser assembly housed in a single enclosure and a method of control is described wherein the tunable laser, pump and semiconductor optical amplifier do not share a common optical axis but are all aligned to optical waveguides on an intervening planar lightwave circuit (PLC). Wavelength monitoring circuitry is included on the PLC to enable monitoring and control of the tunable laser center wavelength and optical bandwidth. The design of the PLC does not introduce perturbations into the swept-source laser output spectrum that would cause artifacts in imaging applications such as optical coherence tomography (OCT).

Abstract: A series of macrocyclic amide compounds and an application thereof. Specifically disclosed are a compound as represented by formula (V) or a pharmaceutically acceptable salt thereof and an application thereof.

Abstract: A method of training a model, an electronic device, and a storage medium are provided, which relate to a field of artificial intelligence, and in particular to a field of reinforcement learning, NLP, etc. The method includes: acquiring a dialogue information; obtaining a predicted information based on the dialogue information by using a first intention recognition model, a first recurrent neural network and a first named entity recognition model; obtaining a machine behavior information based on the predicted information by using a first behavior decision model; acquiring a feedback information for the machine behavior; storing at least one of the predicted information, the machine behavior information, or the feedback information as training data in a database; and performing a model optimization training online based on the training data by using a reinforcement learning algorithm, in response to an amount of the training data reaching a preset data amount.

Abstract: The disclosure relates to the compounds as GPR183 inhibitors, the methods for preparing these compounds, and the compositions and their uses as treatment or prevention of cancers, autoimmune diseases, pain, and osteoporosis using GPR 183 inhibitors targeted immune cells.

Abstract: The present invention relates to anti-CCR8 antibodies and to methods of using anti-CCR8 antibodies. The anti-CCR8 antibodies described herein are useful for the diagnosis and treatment of diseases mediated by CCR8 and/or CCL1, such as various cancers and neuropathic pain associated with abnormal CCL1/CCR8 axis.

Abstract: Provided are compounds of Formula I which can be used as CD38 inhibitors; methods for the production of the compounds; pharmaceutical compositions comprising the compounds; as well as uses and methods for treating a disease mediated by CD38 by administering the compounds.

Abstract: The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.

Abstract: The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.

Abstract: Provided is an amide oxazole compound, in particular a compound, as represented by formula (IV), or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a method for preparing a chlorinated compound, and specifically disclosed is a method for preparing a compound represented by formula (I).

Abstract: The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

Abstract: Provided are a crystal of a compound of formula (I), salt thereof, a crystal of the salt thereof, and a preparation method for the crystal. Also comprised are applications of the compound and the crystal in preparation of drugs for treating IRAK4-related diseases.

Abstract: The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

Abstract: Disclosed are a class of compounds having a highly selective inhibition of ROS1, and the use thereof in the preparation of drugs for treating diseases related to abnormal ROS1 kinase expression. Specifically disclosed are compounds represented by formula (IV) and a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides ROR1 specific chimeric antigen receptors (CAR) and their therapeutic use. The CAR comprises a signal peptide, a ROR1 antigen binding domain, a hinge, a transmembrane domain, a co-stimulatory domain and an intracellular signaling domain. The modified immune cells endowed with such CARs are suitable for treating malignancies such as cancer, chronic lymphocyte leukemia (CLL), and acute lymphocytic leukemia (ALL).

Abstract: The present invention relates to anti-ROR1 antibodies and to methods of using anti-ROR1 antibodies. The anti-ROR1 antibodies described herein are useful for the diagnosis and treatment of diseases, such as various cancers, associated with aberrant expression of ROR1.

Abstract: A compound of formula (II), a tautomer thereof or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of medicaments for treating solid tumor-related diseases.

Abstract: Disclosed in the present invention are an IRAK4 inhibitor, and an application thereof in preparation of a drug for treating IRAK4-related diseases. Specifically disclosed are a compound represented by formula (III) and a pharmaceutically acceptable salt thereof.